# A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation

> **NCT00141167** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 250 (actual)

## Conditions studied

- Smoking Cessation

## Interventions

- **DRUG:** varenicline

## Key facts

- **NCT ID:** NCT00141167
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2010-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141167, "A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00141167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*